Radiation and immunotherapy combo shows promise for tough colon cancers

NCT ID NCT07230639

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial is testing whether a new approach—using targeted radiation that spares lymph nodes, followed by chemotherapy and an immunotherapy drug—can improve outcomes for patients with a specific type of high-risk colon cancer. The study will enroll 52 adults whose tumors are mismatch repair proficient (pMMR) or microsatellite stable (MSS), subtypes that usually don't respond well to immunotherapy alone. The goal is to see if this combination can lead to a complete disappearance of the tumor before surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Node-sparing radiotherapy, chemotherapy (CAPOX), and a PD-1 inhibitor (immune checkpoint drug)
What this could lead to
If successful, this approach could offer a more effective treatment option for patients with a common type of colon cancer that typically does not respond well to immunotherapy alone.
What could go wrong
This is a small, early-phase trial with only 52 participants. The combination therapy may cause more side effects, and the results may not apply to all patients. The long-term benefits are still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE CHECKPOINT THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Sixth Affiliated Hospital of Sun Yat-sen University

    RECRUITING

    Guangzhou, Guangdong, 510655, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.